Up next in our exclusive series of Congress Conversations from the Barcelona event we are delighted to share an interview with Dr Andrew Catchpole, hVIVO. He joined us at the Congress for a presentation and a panel, sharing his insights on human challenge models. We were glad that Dr Catchpole was happy to return for another conversation after our first meeting in Washington; you can watch the earlier interview here. We are grateful to Dr Catchpole for his time and hope you enjoy the interview!
Introducing Dr Catchpole
As Dr Catchpole states, he is Chief Scientific Officer at hVIVO. The company describes itself as a “rapidly growing specialist contract research organisation” and “the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials”.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
